Core Viewpoint - The company has signed an exclusive strategic cooperation agreement with Inmunotek to introduce the Oraltek® series of desensitization drugs to the Chinese market, addressing the significant challenges in the allergy treatment industry and meeting the needs of allergy patients [1] Group 1: Strategic Cooperation - The company will exclusively introduce Inmunotek's Oraltek® series desensitization drugs in China, focusing on domestic sales and registration [1] - This partnership aims to enhance the company's new business in the domestic desensitization drug sector, facilitating the development of the allergy treatment industry [1] Group 2: Clinical Trials and Regulatory Approvals - The company's wholly-owned subsidiary, Shanghai Haobio, has successfully completed the first batch of subject enrollment for the Phase III clinical trial of the desensitization drug MM09 sublingual spray [1] - Three products targeting cat hair, dog hair, and house dust mites have received the "urgent clinical need import permit for Hong Kong and Macau drugs" under the Guangdong Provincial Drug Administration's policy [1]